anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To identify a gene having cartilage differentiation-accelerating action and involved in osteopathy or arthropathy including osteoarthritis, to provide a method for screening substances inhibiting the gene&#39;s function, to provide screened substances, and to provide diagnostic means and medicines using these substances.  &lt;P&gt;SOLUTION: It has been found that Runx3 gene has the action of accelerating cartilage differentiation and is related to osteopathy or arthropathy including osteoarthritis. Therefore, substances that control the function of Runx3 can be served as pharmaceutical preparations for the above diseases. The method for screening such substances is also provided. Furthermore, by analyzing the expression of the Runx3 gene and a protein encoding the same, the diagnostic means or medicines for the above diseases are also provided respectively.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A system, apparatus and method are provide for a lesson to a user of the system. The lesson may be a behavioral lesson or a teaching lesson, such as where knowledge or skill is being imparted to the user. In one aspect, the inventions include a sensor apparatus, the sensor apparatus generating an output indicative of a user&#39;s actions. Memory is provided for storing an individual user profile including at least a plan. and a display. A processor and associated storage comprising a computing platform to generate user feedback
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair treatment composition facilitating the inhibition of occurrence of unpleasant hardness in the hair when repairing a damaged hair protein with a protein derivative, and to provide a method of hair treatment.  &lt;P&gt;SOLUTION: The hair treatment composition contains (A) the protein derivative and (B) a diester. The protein derivative (A) is at least one kind selected from among a silylated protein, an acylated protein and a cationized protein. The diester (B) is a diester of cyclohexane-1,4-dicarboxylic acid with polyoxyethylene alkyl ethers. The hair treatment composition preferably contains (C) a hydrolyzed protein besides them. The method of the hair treatment using the hair treatment composition includes subjecting the hair to hairdye treatment by coating a hairdye composition on the hair after applying the hair treatment composition to the hair.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a royal jelly-decomposing enzyme most suitable for obtaining decomposed products having a high physiological activities such as a functional peptide, etc., from the royal jelly in a good efficiency, and to provide a material containing a royal jelly-decomposing enzyme.  &lt;P&gt;SOLUTION: This material containing royal jelly-decomposing enzyme is prepared by a method including the following processes from the 2-3 day old queen bee larvae of Apis mellifera: (a) a process of centrifugal treatment of the suspension of body tissues of the queen bee larvae at ≤6°C so as to separate to an upper layer of white solid form, a middle layer of solution and a lower layer of precipitate; and (b) a process of recovering the middle layer as the material containing royal jelly-decomposing enzyme. The royal jerry-decomposing enzyme is characterized by being contained in the above material containing royal jerry-decomposing enzyme. The royal jelly-decomposed products are prepared by using the material containing royal jelly-decomposing enzyme or the royal jelly-decomposing enzyme. The method for decomposing the royal jelly is characterized by using the material containing royal jelly-decomposing enzyme or the royal jelly-decomposing enzyme.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To provide a cosmetic containing mucopolysaccharide and lecithin, and having suppressed stickiness caused by mucopolysaccharide and further improved moisturizing effect of mucopolysaccharide. CONSTITUTION:The objective cosmetic contains 0.001-5wt% (preferably 0.1-1%) mucopolysaccharide (e.g. hyaluronic acid, chondroitin-4-sulfate, etc.) and lecithin. The weight ratio of lecithin to mucopolysaccharide is &gt;=1/10. The stickiness characteristic to mucopolysaccharide can be eliminated and the moisturizing effect can be further improved by the combined use of lecithin. The stickiness can be further suppressed by adding a lower alcohol in an am ount of from 2% to 30-40%. The cosmetic can be used in the form of solubilized system, emulsified system, powder dispersion system, etc., however, the merits of the present invention can be fully demonstrated when applied to a transparent or semitransparent face lotion.
PROBLEM TO BE SOLVED: To obtain a stable lycopene powder preparation by including lycopene having a specific crystallinity. SOLUTION: The objective preparation contains lycopene having a crystallinity of &gt;20%, an all-trans isomer content of preferably &gt;=50% and a particle diameter of &lt;10 μm. The content of lycopene in the preparation is preferably 0.5-25 wt.% based on the dried weight of the preparation. The preparation is preferably further incorporated with 10-50 wt.% protective colloid (e.g. gelatin), 20-70 wt.% plasticizer (e.g. saccharose) and/or 0-10 wt.% stabilizer (e.g. α-tocopherol) to improve the stability.  The preparation can be produced by producing a molecularly disperse solution of lycopene e.g. in a water-miscible organic solvent a &gt;=30 deg.C, mixing the solution with an aqueous solution of a protective colloid to transfer a hydrophilic solvent component to the aqueous phase and form a hydrophobic phase in the form of nanodisperse phase, removing the solvent and water from the obtained dispersion and drying the product.
NEW MATERIAL:Deoxycoriolic acid shown by the formula. USE:Useful as a carcinostatic agent, especially effective against mouse Ehrlich ascites carcinoma, having low toxicity. PREPARATION:A microorganism belonging to the genus Coriolus, capable of producing deoxycoriolic acid, is cultivated and the compound shown by the formula is obtained. One example of the microorganism, capable of producing deoxycoriolic acid is strain Coriolus consors PS43a which is Basidiomycetes collected at a forest on a mountain at Ohtsu City in Shiga Prefecture, the strain is inoculated into a medium containing a nutritive source and aerobically grown. Mass production of deoxycoriolic acid is preferably carried out by liquid culture and the culture temperature is usually 15-35 deg.C, preferably 27-32 deg.C. After the cultivation, deoxycoriolic acid is extracted with a water non-compatible organic solvent such as butyl acetate, etc., from a culture filtrate at pH &lt;=9 and collected.
NEW MATERIAL:The compound of formulaI(R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; is group of formula II or formula III), its cyclized lactone, and its pharmacologically permissible salt. EXAMPLE:3-Hydroxy-MB-530B carboxylic acid methyl ester. USE:A remedy for hyperlipemia and a preventive for arteriosclerosis. The compound of formulaIinhibits the synthesis of cholesterol. PROCESS:The compound of formulaIcan be prepared by culturing microorganisms belonging to Syncephalosporum genus, Mucor genus, Rhizopus genus, etc. in a medium containing an MB-530B compound such as MB-530B lactone, MB- 530B carboxylic acid, its pharmacologically permissible salt, MB-530B carboxylic acid alkyl ester, etc., or by contacting an MB-530B compound with the enzyme solution extracted from the above microorganisms.
Stable solid gefarnate compds. were prepd. by mixing gefarnate with antacid Al complds. or Mg compds., e.g., meta magnesium aluminosilicate, magnesium silicate or dry hydroxide gel which was treated with mono saccharides, disaccharides or sugar alcs. to control pka(&lt;=9.3) at its surface.  Thus, 150 g lactose dissolved in 480g H2O, was mixed with 300 g meta magnesium aluminosilicate and dried at 60oC for 17 hr in traydrier.  The obtained powder 500 g was blended with 50g gefarnate to give a powdered product.
PURPOSE:To obtain the titled pharmaceutical, by adding lecithin or polyglycerin fatty acid ester to a system which can be emulsified and dispersed with a sucrose fatty acid ester. CONSTITUTION:A polyglycerin fatty acid ester is added to a sucrose fatty acid ester (a hydrophilic emulsifying and dispersing agent for the preparation of an O/W-type emulsion and having an HLB value of &gt;=6, preferably &gt;=12 is dissolved or dispersed in water in an amount of 0.1-10w/w%, preferably 0.2-5w/w%) emulsifiable and dispersible easily in an acidic solution. The mixture is mixed with oil or fat or lecithin-containing oil or fat, and emulsified and dispersed with an emulsifying and dispersing apparatus such as homomixer to obtain an O/W- type emulsion which is useful as the objective colored pharmaceutical dispersible easily in acidic solution. The ratio of lecithin and/or polyglycerin fatty acid ester to sucrose fatty acid ester is 1/10-20 to 1. EFFECT:The problems such as clouding and precipitation, etc. can be solved.
A total of approximately 120 participants will be recruited. We anticipate that most participants will be identified following referral to rheumatology outpatient or on-call services in National Health Service (NHS) Lothian, or through NHS Lothian's gout liaison service. Additional patients may indicate their willingness to participate directly in response to study advertisements.

Based on baseline renal function and flare frequency, an individual treatment plan will be drawn up for all participants which will set a ceiling on the maximum dose of allopurinol to be used within the trial and determine the need for flare prophylaxis with colchicine. Participants will be randomized to the intervention group in a 1:1 ratio, with stratification by the need for use of flare prophylaxis.

All participants will have a smart phone application (GoutSMART) uploaded to their smart phones. Usual care participants will have a limited version of the GoutSMART application installed which includes background information about gout and provides a means for participants to maintain diaries of gout flares. Subjects in the usual care arm of the study will have treatment escalation decisions made by their GPs. Subjects in the treat-to-target arm will be taught to self-test serum urate using a BeneCheck Plus hand held device and provided with test strips. A full version of the GoutSMART application will be installed with the features mentioned above but also the facility to record a urate diary. Participants will be prompted to check their serum urate and enter the results into the GoutSMART application. Participants reporting a urate level \&gt;0.3mmol/l will be advised to increase the dose of allopurinol incrementally as specified in their treatment plan. No change will be advised in those whose urate levels are already at target. If the patient needs to increase allopurinol there will be an automatic reminder after two weeks prompting the patients to submit updated self-test results which will be handled in the same way as described above. Conversely for participants achieving target levels this will be acknowledged and a request to resubmit readings will be sent on a monthly basis.
The present invention relates to an emergency treatment system, which includes a working host, a physician order system, and a pricing system. The working host provides an emergency treatment information platform which includes a recommended treatment field, a recommended dosing field, a detailed treatment field, and a recording field. According to a patient&#39;s current status, the recommended treatment field shows emergency treatment options in order; the recommended dosing field shows applicable dosing options; the detailed treatment field shows detailed treatment options; the recording field shows an emergency treatment record after the treatment according to said recommended treatment field, said recommended dosing field, and said detailed treatment field. The emergency treatment record can be exported to the physician order system as a physician information. Also, the drug types and drug dosages shown in the recommended dosing field as well as the consumable type and consumable amount shown in the detailed treatment field can be exported to the pricing system for pricing. Thereby, the time it takes for medical staffs to record the emergency treatment is reduced, the recording errors such as mistakes and omissions are reduced, and the handover at change of shift is more smooth.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a plant infection controlling agent and a fungal external preparation free from phytotoxicity and effective against infectious disorders of crops and fungal skin diseases of animals at a low cost.  &lt;P&gt;SOLUTION: A microbial bed 3 in which a porous body in which a microorganism (an indicated microorganism) is fixed as a treating medium, e.g. wood chip such as sawdust is used and used tea leaves are stored in a treating tank 1. A material obtained by fixing a mixture of lignin-decomposing bacterium with heat-resistant actinomyces, white decay basidiomycete, cellulose decomposing bacterium, anaerobic spore-bearing bacillus, mold, Proteolytic bacterium and Bacillus subtilis on the sawdust is used as a treating medium as the microbial bed 3. A gas discharge pipe 8 is constituted so as to be able to discharge a gas (nitrogen/carbon dioxide) containing stream generated in a treating tank 1. The steam in the discharged gas is formed as dew condensation by a cooler 10 and treated as a clean water (hereinafter referred to as water treated with used tea leaves) and the gas component is passed through a septic tank (not shown in the figure) and discharged as harmless air.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The invention concerns a method for conducting business at a medical practice. The method includes acquiring a customizable medical database containing information about medical conditions, and personalizing the database with details of the medical practice. The method further includes providing consultations at the medical practice, including identification of a patient&#39;s condition. The method further includes selecting subject matter relevant to the patient&#39;s condition in a database query and printing an information sheet from the database in response to the query. The information sheet is automatically personalized to identify the medical practice and to contain information about the patient&#39;s condition. The invention further concerns a customizable database containing information about medical conditions. The database is operable to personalize it with details of a medical practice and to select subject matter relevant to a patient&#39;s condition in a database query so that an information sheet can be selectively printed from the database in response to the query. The information sheet is automatically personalizable to identify the medical practice and information about the patient&#39;s condition.
PURPOSE: A composition containing sea algae extract for preventing or treating inflammatory diseases is provided to use in medicinal and pharmaceutical product, health functional food or functional feed. CONSTITUTION: A pharmaceutical composition for preventing or treating inflammatory diseases contains Dictyopteris divaricata extract, Scytosiphon lomentaria extract, or Ishige okamurae extract as an active ingredient. The sea algae extract is isolated using water, low alcohol of C1-C4, or their mixture solvent. The low alcohol is methanol or ethanol. The inflammatory diseases are osteoarthritis, rheumatoid arthritis, ventilation, fibromyalgia, psoriatic arthritis, asthma, atopy, crohn&#39;s disease and ulcerative colitis. A functional health food composition for preventing or treating inflammatory diseases contains the sea algae extract as an active ingredient.
The present invention discloses the recipe and preparation process of gastrodia tuber capsule. Gastrodia tuber capsule is prepared through water extracting ten kinds of Chinese medicinal materials, including gastrodia tuber, achyranthes root, figwort, rehmannia root, angelica, etc. to obtain decoction; mixing with fine powder of scorpion, vitamin B1, etc.; and encapsulating. The medicine has the functions of invigorating liver and kidney, nourishing Yin, suppressing the sthenic Yang, dispelling wind evil, strengthening physique, promoting blood circulation to disperse blood clots, etc. and is suitable for treating polyneuritis, trigeminal neuralgia, Bell&#39;s palsy, optic neuritis, protrusion of lumbar intervertebral disc, etc.
PURPOSE:To obtain an antacid composition capable of keeping pH in the stomach within the optimum range and producible by a simple method. CONSTITUTION:This antacid composition contains an antacid substance, a polymer compound soluble in an acid region and a compound insoluble in an acid region. The composition is produced, e.g. by using a polymer compound soluble in an acid region and a compound insoluble in an acid region as binders and granulating the antacid substance from a primary particle to a tertiary particle. In this production method, the particle size of the antacid substance as the raw material is preferably &lt;=100mum, especially 1 to 50mum. The weight ratio of the antacid substance: the polymer compound soluble in an acid region: the compound insoluble in an acid region is preferably 100:1 to 20:0.5 to 5 especially 100:5 to 10:1 to 3.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a solubilizing agent in which polyglycerin fatty acid ester is used and which can be used in foods, medicines and cosmetics and can give a solubilization composition, which disperses an oil-soluble substance minutely in a water phase without using a special emulsifying machine even when a large quantity of the oil-soluble substance is blended and which has high transparency, and to provide foods, medicines and cosmetics in each of which the solubilizing agent is used.  &lt;P&gt;SOLUTION: The solubilizing agent is composed of polyglycerin fatty acid ester. A fatty acid constituting the polyglycerin fatty acid ester is composed of one or more saturated fatty acids (a) selected from 8-22C saturated fatty acids and one or more unsaturated fatty acids (b) selected from 16-22C unsaturated fatty acids. The molar ratio ((a)/(b)) of the saturated fatty acids (a) to the unsaturated fatty acids (b) is within 0.2/0.8 to 0.8/0.2. Foods, medicines and cosmetics in each of which the solubilizing agent is used are provided.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an RNA-modifying protein capable of changing the structure of an mRNA in a direction for improving a protein synthesis efficiency, a protein synthesis-promoting agent easily improving the protein synthesis efficiency, a gene therapeutic agent easily enhancing a translational efficiency of a transgene, and a cancer-treating agent capable of performing the treatment of cancer easily and effectively.  &lt;P&gt;SOLUTION: The RNA-modifying protein has a translational structure specific RNAase activity excising a sequence in a non-translational zone (5&#39;UTR, 3&#39;UTR) in the mRNA and an RNA-unwinding activity for unwinding the mRNA having a higher structure to stabilize it at a primary structure. The protein synthesis- promoting agent contains the RNA-modifying protein or a gene encoding the protein. The gene therapeutic agent contains the transgene and the protein synthesis-promoting agent. The cancer-treating agent contains the RNA- modifying protein, an antibody against a partial peptide of the protein or an anti-sense nucleotide against the protein or a gene encoding a part of it.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The present invention relates to sleepiness assessment. In order to provide a more accurate measure to predict OSA severity, an apparatus is provided for sleepiness assessment. The apparatus comprises an input unit, a processing unit, and an output unit. The input unit is configured to receive data indicative of an activity currently performed by a user. The processing unit is configured to determine, based on the activity currently performed by the user, a current situation the user is engaging in. The processing unit is configured to determine whether the current situation matches one of a plurality of pre-determined situations used for situational sleepiness assessment. In response to the determination that the current situation matches one of the plurality of predetermined situations, the processing unit is configured to send a notification to the user for a self-report of a user&#39;s current subjective sleepiness level and/or obtain a user&#39;s current objective sleepiness level from sensor data. The processing unit is further configured to generate, based on the determined situation and the user&#39;s current subjective and/or objective sleepiness level, a situational sleepiness profile indicative of a sleep disturbance on daytime sleepiness in specific situations. The output unit is configured to provide the generated situational sleepiness profile, which is preferably useable to support sleep apnea diagnostics.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for detecting cancer, to provide a pharmaceutical composition for treating the cancer, and to provide a method for screening a substance inhibiting the cancer.  &lt;P&gt;SOLUTION: This method for detecting the cancer includes measuring expression of an Egf17 gene. An antibody specifically combines with an Egf17 polypeptide or a fragment thereof. The pharmaceutical composition for treating the cancer contains an Egf17 polynucleotide and/or a derivative thereof or the Egf17 polypeptide and/or a derivative thereof. The method for screening the substance inhibiting the cancer includes selecting a substance inhibiting the expression of the Egf17 gene or a substance accelerating the expression.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a blood circulation-improving composition having excellent blood circulation-improving effect and further having high safety and practicality and being widely useable for beverages and foods, feed, quasi-drugs, medicines, etc.  &lt;P&gt;SOLUTION: The blood circulation-improving composition comprises ellagitannin as an active ingredient. The blood circulation-improving composition comprises at least one selected from a group consisting of elaeocarpusin, chebulagic acid, geraniin and corilagin as ellagitannin as an active ingredient. These ingredients are derived from natural plants having actual results taken in human bodies over a long period, e.g, amla and are free from fear inducing strong adverse action even if they are taken in human bodies in large amounts and have high safety. Therefore, the composition has high practicality and can widely be used for beverages and foods, feed, quasi-drugs, medicines, etc.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a safe, tasteless and odorless fibroblast-proliferation accelerator.  &lt;P&gt;SOLUTION: A peptide composition comprising peptides which are decomposition products of gelatin and/or collagen, having 1,000-10,000 molecular weight and containing 15-25 mol% sum total of acidic amino acid units of aspartic acid units and glutamic acid units is provided. The fibroblast-proliferation accelerator contains the peptide composition. The peptide composition is produced by separating the peptides by using difference of isoelectric points in a solution containing decomposition products of gelatin and/or collagen. The method for producing the peptide composition includes a process for bringing the solution containing the decomposition products of gelatin and/or collagen to be adsorbed with an anion exchange resin and a process for eluting the peptide from the anion exchange resin.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI